New Vaccines for Chronic Respiratory Patients

Arch Bronconeumol. 2024 Sep;60(9):565-575. doi: 10.1016/j.arbres.2024.05.026. Epub 2024 May 31.
[Article in English, Spanish]

Abstract

Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients' quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.

Keywords: Chronic respiratory diseases; Influenza; Monoclonal antibody; Pertussis; Pneumococcal disease vaccine; Respiratory syncytial virus; SARS-CoV-2; Vaccine.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines*
  • Chronic Disease
  • Humans
  • Influenza Vaccines
  • Pertussis Vaccine / therapeutic use
  • Pneumococcal Vaccines
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory Tract Infections / prevention & control
  • Vaccination

Substances

  • COVID-19 Vaccines
  • Influenza Vaccines
  • Pneumococcal Vaccines
  • Pertussis Vaccine